A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer

Trial Profile

A Phase I, Multi-Center, Open Label, Dose Escalation, Safety, PK and PkD Study of Orally Administered SGX523, a Small Molecule Anti-Cancer Agent, on a Twice Daily, Uninterrupted Schedule in Patients With Advanced Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2008

At a glance

  • Drugs SGX 523 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors SGX Pharmaceuticals
  • Most Recent Events

    • 22 Jul 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 May 2008 Further drug development discontinued due to observed toxicities, according to an SGX Pharmaceuticals media release.
    • 27 Mar 2008 Dose limiting toxicity was observed earlier than anticipated; no patients are currently being treated in the interrupted dose trial and patient are continuing treatment at the lower dose level in the continuous dosing trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top